Image

Hosted by Professor Leonie Quinn

Developing Novel Antibody Drug Conjugate Therapies for the Treatment of Brain Cancer

Career Summary: Prof Bryan Day is the Group Leader of the Sid Faithfull Brain Cancer Laboratory at the QIMR Berghofer Medical Research Institute in Brisbane, as well as the Co-Director of the Children's Brain Cancer Centre (CBCC) and Co-Director of the Australian Brain Cancer Research Alliance (ABCARA). He obtained his PhD in Medical Sciences from the University of Queensland in 2008. His focus, over the last 20+ years, has been as a primary researcher studying the biology and development of novel antibody drug conjugate (ADC) therapies to treat adult and paediatric brain cancers. Recently, Prof Day and team spearheaded an international collaborative study to explore the role of OLIG2, and evaluate the efficacy of the small molecule OLIG2 inhibitor CT-179, in paediatric medulloblastoma, culminating in a recent publication in Nature Communications (Li et al.,….. Day 2025). This work has led to initiation of the Phase 1 first in human CT-179 Opal trial, commencing nationally in Australia in early 2026.